文献速递生殖医学

接受辅助生殖技术患者精液、阴道分泌物、卵泡液及卵巢髓质中SARS-CoV-2污染风险

Risk of contamination of semen, vaginal secretions, follicular fluid and ovarian medulla with SARS-CoV-2 in patients undergoing ART.
PubMed 文献 · Hum Reprod · 2022-01-01

该观察性队列研究在2020年9月至2021年4月布鲁塞尔第二波疫情期间,对接受辅助生殖技术(ART)的无症状患者留取精液、卵泡液、阴道分泌物及卵巢组织冻存残余髓质样本行RT-qPCR检测。共分析291例患者的394份样本,所有样本均未检出SARS-CoV-2病毒RNA,无论分诊问卷和鼻咽拭子检测结果如何。

要点

  • 无症状ART患者的精液、卵泡液、阴道分泌物及卵巢髓质中均未检出SARS-CoV-2 RNA。
  • 共分析291例患者的394份样本,结果不受分诊问卷和鼻咽拭子检测结果影响。
  • 研究提示IVF与男科实验室无需额外采取防止工作人员或患者间污染的措施。

核心结论

  • 无症状接受ART的患者中,精液、卵泡液、阴道分泌物及卵巢组织冻存残余髓质均未检出SARS-CoV-2 mRNA,与分诊问卷和鼻咽拭子检测结果无关。
  • 研究提示无症状患者生殖道无SARS-CoV-2污染风险,IVF与男科实验室无需额外实施防止工作人员或患者间污染的措施。

研究设计与样本

  • 观察性队列研究,纳入2020年9月至2021年4月布鲁塞尔第二波疫情期间接受ART(IUI、IVF/ICSI、卵子及卵巢组织冻存)患者的残余材料样本。
  • 样本包括精液、卵泡液、阴道分泌物及卵巢髓质,共分析291例患者的394份样本。
  • 所有患者于周期开始和结束时填写分诊问卷,操作前按标准建议采集鼻咽拭子行RT-PCR检测SARS-CoV-2 RNA;精液分析仅要求采样前一天填写问卷。
  • 鼻咽拭子SARS-CoV-2 RNA检测和/或问卷阳性的患者除无法推迟者外,其ART周期被取消。

主要发现

  • 共分析394份来自291例患者的样本,所有样本中均未检出SARS-CoV-2病毒RNA。
  • 20份样本来自分诊问卷阳性但鼻咽拭子SARS-CoV-2检测阴性的患者。
  • 另20份样本来自鼻咽拭子SARS-CoV-2检测阳性的患者。
  • 其余样本来自鼻咽拭子SARS-CoV-2检测和/或分诊问卷阴性或未知的患者。

临床怎么用

  • 研究提示无症状患者生殖道无SARS-CoV-2污染风险,与分诊问卷或鼻咽拭子SARS-CoV-2检测结果无关。
  • 研究提示IVF与男科实验室无需额外实施防止工作人员或患者间污染的措施。

局限性

  • 由于取消政策,纳入分析的分诊问卷阳性或鼻咽拭子SARS-CoV-2检测阳性患者的样本数量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA be detected in the reproductive tract of asymptomatic patients undergoing ART? SUMMARY ANSWER: SARS-CoV-2 mRNA is not detectable in semen, follicular fluid, vaginal secretions or residual medulla from ovarian tissue cryopreservation procedures in asymptomatic patients who undergo ART, irrespective of the results of a triage questionnaire and a nasopharyngeal SARS-CoV-2 RNA detection test. WHAT IS KNOWN ALREADY: The SARS-CoV-2 pandemic had a huge impact on the activities of fertility clinics. Although some studies reported the presence of SARS-CoV-2 mRNA in the reproductive system during or after acute COVID-19 symptomatic infections, uncertainties remain regarding the presence of viral mRNA in the reproductive material and follicular fluid of asymptomatic patients undergoing ART. STUDY DESIGN, SIZE, DURATION: An observational cohort trial of residual material samples including semen, follicular fluid, vaginal secretions and ovarian medulla was conducted during the second pandemic wave in Brussels from September 2020 to April 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: All patients who underwent ART (IUI, IVF/ICSI, oocyte and ovarian tissue cryopreservation) responded to a triage questionnaire at the beginning and end of the cycle and underwent nasopharyngeal swab collection for SARS-CoV-2 RNA detection by RT-PCR before the procedure according to standard recommendations. For semen analysis, only the questionnaire was requested the day before the sample collection. The ART cycles of patients with positive nasopharyngeal SARS-CoV-2 RNA detection tests and/or questionnaires were cancelled except for those that could not be postponed. After providing informed consent, swabs on residual materials were collected the day of the oocyte, ovarian tissue or semen collection and were processed for RT-qPCR. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 394 samples from 291 patients were analysed. Amongst them, 20 samples were obtained from patients with a positive questionnaire but negative nasopharyngeal SARS-CoV-2 test and 20 others were from patients with a positive nasopharyngeal SARS-CoV-2 test. The remaining samples were collected from patients with a negative or unknown nasopharyngeal SARS-CoV-2 test and/or a negative or unknown triage questionnaire. Viral RNA for SARS-CoV-2 was undetectable in all of the samples. LIMITATIONS, REASONS FOR CAUTION: Considering the cancellation policy, only a limited number of samples from patients with positive triage questionnaires or nasopharyngeal SARS-CoV-2 tests were included in the analysis. WIDER IMPLICATIONS OF THE FINDINGS: The study suggested that there was no risk of reproductive tract contamination by SARS-CoV-2 in asymptomatic patients, irrespective of the results from a triage questionnaire or nasopharyngeal SARS-CoV-2 test. The results suggested that no additional measures to prevent staff or cross-patient contamination need to be implemented in the IVF and andrology laboratories. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the Université Libre de Bruxelles and by a grant from Ferring. A.D. and I.D. received a grant from Ferring for the study. The authors have no other conflict of interest to declare related to this study. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Kteily K, Pening D, Diaz Vidal P, et al. Risk of contamination of semen, vaginal secretions, follicular fluid and ovarian medulla with SARS-CoV-2 in patients undergoing ART. Hum Reprod. 2022. PMID: 34741508. doi:10.1093/humrep/deab255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。